- iCAD, Inc. appoints Mark Koeniguer as Chief Commercial Officer to spearhead global expansion.
- Analyst forecasts indicate a significant potential upside with an "Outperform" recommendation.
- Current GF Value suggests a slight downside from the current stock price.
iCAD, Inc. (ICAD, Financial) has strategically bolstered its leadership by appointing Mark Koeniguer as Chief Commercial Officer. With a robust background spanning over 30 years in the MedTech and AI sectors, Koeniguer's prior success at ScreenPoint Medical—where he significantly boosted revenue—positions him well to drive iCAD's global commercial sales and operations.
Wall Street Analysts Forecast
Analyst projections for iCAD Inc (ICAD, Financial) reflect an optimistic outlook. Four analysts have set a one-year average price target of $4.75, with predictions ranging from a high of $9.00 to a low of $3.00. This average target suggests a potential upside of 146.11% from the current stock price of $1.93. For further insights, visit the detailed icad Inc (ICAD) Forecast page.
iCAD Inc's (ICAD, Financial) average brokerage recommendation score stands at 1.8, indicating an "Outperform" status from four brokerage firms. On the rating scale where 1 implies a Strong Buy and 5 a Sell, this rating underscores favorable sentiment among analysts.
GF Value Estimation
According to GuruFocus estimates, the projected GF Value of iCAD Inc (ICAD, Financial) in one year is calculated at $1.81. This estimation translates into a potential downside of 6.22% from the current stock price of $1.93. The GF Value is derived from historical trading multiples, past business growth, and future performance projections. Explore more detailed data on the icad Inc (ICAD) Summary page.
